Stock MGTX MEIRAGTX HOLDINGS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company MeiraGTx Holdings plc

Equities

MGTX

KYG596651029

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
5.14 USD -2.74% Intraday chart for MeiraGTx Holdings plc -7.22% -26.78%
May. 15 Transcript : MeiraGTx Holdings plc Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM
May. 09 Earnings Flash (MGTX) MEIRAGTX Reports Q1 Revenue $697,000 MT

Business Summary

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.

Number of employees: 402

Sales per Business

USD in Million2022Weight2023Weight Delta
Retinal Drugs and Gene Therapies
100.0 %
16 100.0 % 14 100.0 % -11.95%

Sales per region

USD in Million2022Weight2023Weight Delta
United Kingdom
100.0 %
16 100.0 % 14 100.0 % -11.95%

Managers

Managers TitleAgeSince
Richard Giroux FOU
 Founder 61 15-03-19
Alexandria Forbes CEO
 Chief Executive Officer 59 15-03-19
Robert Zeldin CTO
 Chief Tech/Sci/R&D Officer 61 20-08-04
Elizabeth Anderson IRC
 Investor Relations Contact - 18-12-31
Tim Randall AUD
 Comptroller/Controller/Auditor - 19-03-31
Robert Wollin LAW
 General Counsel 48 19-07-31
Stuart Naylor PRN
 Corporate Officer/Principal 61 15-03-31

Members of the board

Members of the board TitleAgeSince
Debra Yu BRD
 Director/Board Member 59 22-04-24
Thomas Shenk BRD
 Director/Board Member 77 15-05-31
Keith Harris CHM
 Chairman 71 15-05-31
Nicole Seligman BRD
 Director/Board Member 66 19-05-09
Alexandria Forbes CEO
 Chief Executive Officer 59 15-03-19
Stuart Naylor PRN
 Corporate Officer/Principal 61 15-03-31
Martin Indyk BRD
 Director/Board Member 72 19-02-20
Ellen Hukkelhoven BRD
 Director/Board Member 37 17-09-30
Neil Mendoza BRD
 Director/Board Member 64 15-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 64,306,613 41,807,754 ( 65.01 %) 0 65.01 %

Shareholders

NameEquities%Valuation
Perceptive Advisors LLC
17.64 %
11,331,103 17.64 % 53 M $
Johnson & Johnson Innovation - JJDC, Inc.
10.34 %
6,641,064 10.34 % 31 M $
Adage Capital Partners GP LLC
8.240 %
5,291,618 8.240 % 25 M $
SANOFI
7.315 %
4,697,737 7.315 % 22 M $
Prosight Management LP
6.256 %
4,017,301 6.256 % 19 M $
Adena Estate, Inc.
5.087 %
3,266,806 5.087 % 15 M $
683 Capital Management LLC
3.893 %
2,500,000 3.893 % 12 M $
BlackRock Advisors LLC
3.216 %
2,065,445 3.216 % 10 M $
Alexandria Forbes
2.182 %
1,401,489 2.182 % 7 M $
Richard Giroux
1.449 %
930,578 1.449 % 4 M $

Company contact information

MeiraGTx Holdings Plc

450 East 29th Street 14th floor

10016, New York

+646 860 7985

http://www.meiragtx.com
address MeiraGTx Holdings plc(MGTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for MeiraGTx Holdings plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.14 USD
Average target price
21.2 USD
Spread / Average Target
+312.45%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MEIRAGTX HOLDINGS PLC Stock MeiraGTx Holdings plc
-26.78% 340M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.83% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.80% 106B
BIONTECH SE Stock BioNTech SE
-10.84% 23.4B
ARGENX SE Stock argenx SE
-1.69% 22.1B
GENMAB A/S Stock Genmab A/S
-10.23% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.11% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.62% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.53% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MGTX Stock
  4. Company MeiraGTx Holdings plc